Hathorne, Heather R |
NCT03624101: Novel Therapeutic Approaches for Treatment of CF Patients with W1282X Premature Termination Codon Mutations |
|
|
| Completed | 4 | 2 | US | Trikafta, symdeko/Trikafta, Ivacaftor/Trikafta | University of Alabama at Birmingham | Cystic Fibrosis | 12/24 | 12/24 | | |
| Recruiting | 4 | 730 | Canada, US | Beta-lactam antibiotic, β-lactam, Aminoglycoside, AG | Chris Goss, University of Washington, Medical University of South Carolina, Cystic Fibrosis Foundation | Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation | 11/26 | 11/26 | | |
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension |
|
|
| Recruiting | 3 | 234 | US | Clofazimine Inhalation Suspension, MNKD-101, Placebo | Mannkind Corporation | MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous | 08/26 | 12/28 | | |
NCT05495243: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough |
|
|
| Completed | 2 | 40 | US | ARINA-1, Placebo | Renovion, Inc. | Non-cystic Fibrosis Bronchiectasis | 01/24 | 03/24 | | |
| Recruiting | 1/2 | 40 | US | 4D-710 | 4D Molecular Therapeutics | Cystic Fibrosis Lung | 12/26 | 01/30 | | |
| Recruiting | 1 | 20 | US | Symdeko, Orkambi, Ivacaftor | University of Alabama at Birmingham | Cystic Fibrosis | 01/26 | 09/26 | | |
NCT04075864: Feasibility of a New Model for Exercise Prescription in Cystic Fibrosis |
|
|
| Recruiting | N/A | 12 | US | Behavioral Counseling and Exercise | University of Alabama at Birmingham | Cystic Fibrosis | 12/25 | 12/26 | | |
| Recruiting | N/A | 60 | US | | University of Alabama at Birmingham, Massachusetts General Hospital | Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis | 12/24 | 12/24 | | |
CHEC-SC, NCT03350828: CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes |
|
|
| Active, not recruiting | N/A | 5000 | US | | Nicole Hamblett, Cystic Fibrosis Foundation | Cystic Fibrosis | 12/26 | 12/26 | | |
NCT06504589: A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators |
|
|
| Recruiting | N/A | 400 | US | | Nicole Hamblett, Washington University School of Medicine, Florida State University, University of North Carolina, Chapel Hill, University of Toronto, Cystic Fibrosis Foundation | Cystic Fibrosis | 08/29 | 08/29 | | |
| Recruiting | N/A | 500 | US | | George Solomon, Cystic Fibrosis Foundation | Cystic Fibrosis | 12/25 | 12/26 | | |
NCT04680403: Video Telehealth Exercise Training in Cystic Fibrosis |
|
|
| Recruiting | N/A | 25 | US | Exercise, Behavior Change Coaching | University of Alabama at Birmingham | Cystic Fibrosis | 01/25 | 12/25 | | |
BEGIN, NCT04509050: Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children |
|
|
| Recruiting | N/A | 210 | US | Ivacaftor or elexacaftor/tezacaftor/ivacaftor, Kalydeco or Trikafta, Vertex (VX)-770 or VX-445/VX-661/VX-770 | Sonya Heltshe, Cystic Fibrosis Foundation, University of Washington, University of Alabama at Birmingham | Cystic Fibrosis | 12/29 | 12/29 | | |
| Active, not recruiting | N/A | 285 | US | | Amalia Magaret, University of Texas, National Jewish Health, Cystic Fibrosis Foundation | Pregnancy Related, Cystic Fibrosis | 12/26 | 12/26 | | |